Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Lux Health Tech Acquisition (LUXAU)
Upcoming IPO
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Roman DBDR Tech Acquisition (DBDRU)
Atlas Crest Investment Corp. (ACICU)
Caliber Home Loans, Inc. (HOMS)
Allegro MicroSystems, Inc. (ALGM)
Mavenir plc (MVNR)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
AmeriHome, Inc. (AHM)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Bluescape Opportunities Acquisition (BOAC.U)
Absolute Software (ABST)
Priced IPO
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
More companies

Inozyme Pharma, Inc. (INZY)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Through their in-depth understanding of the biological pathways involved in mineralization, they are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. They are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Their lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. This pathway is central to the regulation of calcium deposition throughout the body and is further associated with neointimal proliferation, or the overgrowth of smooth muscle cells inside blood vessels. They have generated robust preclinical proof of concept data demonstrating that in animal models INZ-701 prevented pathological calcification, led to improvements in overall health and survival and prevented neointimal proliferation. They plan to file an IND with the FDA and CTAs with regulatory authorities in Europe in the second half of 2020.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Axel Bolte Stephen Basso
Employees Founded
24 2015

Contacts

Address: 321 Summer Street, Suite 400, Boston, MA 02210, USA

Telephone: (857) 330-4340

Web page: http://www.inozyme.com

IPO information

Expected Date 7/24/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $349
Revenues (MM) $0
Net Income (Loss) (MM) $-22.5

Voting

What do you think will happen with the INZY share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 5
Shares Revised (MM) 7
Expected offer amount (MM) $75
Realized offer amount(MM) $112
Underwriters
BofA Securities/ Cowen/ Piper Sandler
CO-Managers
Wedbush PacGrow

Sector: Healthcare

Tweets about $INZY

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats